Skip to content

D&A at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$101M-4.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.28M+30.8%
Viatris logo
ViatrisVTRS
$676.1M+1.7%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$295M-3.3%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$197K-10.5%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$4.11M-10.7%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's D&A?
Harrow (HROW) reported D&A of $455K in Q1 2026.
How has Harrow's D&A changed year-over-year?
Harrow's D&A decreased by 2.2% year-over-year, from $465K to $455K.
What is the long-term trend for Harrow's D&A?
Over 4 years (2021 to 2025), Harrow's D&A has grown at a 2.8% compound annual growth rate (CAGR), from $1.72M to $1.92M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.